LivaNova PLC Stock price

Equities

LIVN

GB00BYMT0J19

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-02-26 pm EST 5-day change 1st Jan Change
55.97 USD -2.01% Intraday chart for LivaNova PLC +12.21% +8.18%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 1.15B Sales 2024 * 1.2B Capitalization 3.02B
Net income 2023 17M Net income 2024 * 63M EV / Sales 2023 2.42 x
Net cash position 2023 * 52.96M Net cash position 2024 * 169M EV / Sales 2024 * 2.37 x
P/E ratio 2023
162 x
P/E ratio 2024 *
43.9 x
Employees 2,900
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.01%
1 week+12.21%
Current month+14.98%
1 month+12.98%
3 months+26.86%
6 months+0.43%
Current year+8.18%
More quotes
1 week
55.12
Extreme 55.12
57.80
1 month
47.79
Extreme 47.79
57.80
Current year
47.79
Extreme 47.79
57.80
1 year
40.26
Extreme 40.26
59.86
3 years
40.26
Extreme 40.26
93.89
5 years
33.40
Extreme 33.4
99.13
10 years
33.40
Extreme 33.4
131.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 18-06-11
Director of Finance/CFO 54 16-12-31
Investor Relations Contact - 22-07-31
Members of the board TitleAgeSince
Director/Board Member 63 20-12-02
Director/Board Member 64 22-06-12
Chief Executive Officer 72 18-06-11
More insiders
Date Price Change Volume
24-02-26 55.97 -2.01% 434,974
24-02-23 57.12 +1.56% 708,803
24-02-22 56.24 -1.02% 626,373
24-02-21 56.82 +8.02% 1,492,705

Delayed Quote Nasdaq, February 26, 2024 at 04:00 pm EST

More quotes
LivaNova PLC is a global medical device company. The Company designs, develops, manufactures, and sells products and therapies to provide improvements for both the head and heart. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the development, production and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannulae and other related accessories. The Neuromodulation segment is engaged in the design, development, and marketing of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the LivaNova Vagus Nerve Stimulation Therapy (VNS Therapy) System, is an implantable device for the treatment of DRE and DTD. The ACS segment is engaged in the development, production, and sale of temporary life support products.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
55.97 USD
Average target price
65.7 USD
Spread / Average Target
+17.38%
Consensus
  1. Stock
  2. Equities
  3. Stock LivaNova PLC - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW